Viatris (VTRS) Cash & Equivalents (2019 - 2026)
Viatris (VTRS) posted Cash & Equivalents of $886.5 million for Q2 2026, down 50.86% on a QoQ basis from $1.8 billion in Q1 2026, and up 56.51% year-over-year from $566.4 million in Q2 2025.
Analysis
Viatris (VTRS) Cash & Equivalents (2019 - 2026) Analysis & Trends
Viatris has reported Cash & Equivalents for 8 years, with the latest figure at $886.5 million in Q2 2026.
- On a quarterly basis, Cash & Equivalents rose 56.51% year-over-year to $886.5 million in Q2 2026; TTM through Jun 2026 was $886.5 million, a 56.51% increase from a year earlier, with the FY2025 full-year figure at $1.3 billion, up 79.65% from the prior year.
- Cash & Equivalents was $886.5 million for Q2 2026 at Viatris, down from $1.8 billion in the prior quarter.
- The five-year high for Cash & Equivalents was $1.9 billion in Q3 2024, with the low at $506.6 million in Q1 2023.
- Average Cash & Equivalents over 5 years is $978.9 million, with a median of $901.8 million recorded in 2024.
- The sharpest annual moves came in 2025 and 2026: Cash & Equivalents sank 48.09% in 2025, then soared 138.97% in 2026.
- Over 5 years, Cash & Equivalents stood at $1.3 billion in 2022, then fell by 21.43% to $991.9 million in 2023, then decreased by 25.79% to $736.1 million in 2024, then surged by 79.65% to $1.3 billion in 2025, then plunged by 32.96% to $886.5 million in 2026.
- The last three Cash & Equivalents figures came in at $886.5 million (Q2 2026), $1.8 billion (Q1 2026), and $1.3 billion (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.53 Bn | 38.88 Bn | 2.15 Bn | 3.66 Bn |
| 2 | Viatris | 19.14 Bn | 18.25 Bn | 1.46 Bn | 886.50 Mn |
| 3 | Dr Reddys Laboratories | 9.86 Bn | 9.69 Bn | 396.53 Mn | 118.35 Mn |
| 4 | Amneal Pharmaceuticals | 5.45 Bn | 5.33 Bn | 334.51 Mn | 127.64 Mn |
| 5 | Bausch Health Companies | 2.33 Bn | 492.63 Mn | 2.10 Bn | 1.83 Bn |
| 6 | Alvotech | 1.51 Bn | 1.36 Bn | 2.56 Mn | 142.75 Mn |
| 7 | Ani Pharmaceuticals | 1.48 Bn | 1.12 Bn | 165.89 Mn | 360.21 Mn |
| 8 | Amphastar Pharmaceuticals | 992.90 Mn | 702.78 Mn | 93.47 Mn | 223.61 Mn |
| 9 | Fennec Pharmaceuticals | 400.20 Mn | 358.95 Mn | 17.15 Mn | 41.25 Mn |
| 10 | RedHill Biopharma | 178.79 Mn | 178.79 Mn | - | 3.97 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 886.50 Mn |
| Mar 31, 2026 | 1.80 Bn |
| Dec 31, 2025 | 1.32 Bn |
| Sep 30, 2025 | 975.30 Mn |
| Jun 30, 2025 | 566.40 Mn |
| Mar 31, 2025 | 755.00 Mn |
| Dec 31, 2024 | 736.10 Mn |
| Sep 30, 2024 | 1.88 Bn |
| Jun 30, 2024 | 917.20 Mn |
| Mar 31, 2024 | 1.01 Bn |
| Dec 31, 2023 | 991.90 Mn |
| Sep 30, 2023 | 1.31 Bn |
| Jun 30, 2023 | 629.20 Mn |
| Mar 31, 2023 | 506.60 Mn |
| Dec 31, 2022 | 1.26 Bn |
| Sep 30, 2022 | 646.70 Mn |
| Jun 30, 2022 | 664.70 Mn |
| Mar 31, 2022 | 752.40 Mn |
| Dec 31, 2021 | 706.20 Mn |
| Sep 30, 2021 | 756.60 Mn |